Healthcare Industry News: Captisol-enabled
News Release - November 20, 2007
CyDex Announces New Corporate Name
Changes Name to "CyDex Pharmaceuticals, Inc." to Reflect Current Focus on Acute Care Hospital ProductsLENEXA, Kan.--(HSMN NewsFeed)--CyDex, Inc. announced today that it has changed its name to “CyDex Pharmaceuticals, Inc.” CyDex changed its name to reflect its current focus on developing and commercializing its pharmaceutical product candidates. Historically, CyDex’s focus had been on the licensing of its CAPTISOL® technology to pharmaceutical companies.
Future steps in this change of identity will include enhancements to the corporate website (now www.cydexpharma.com).
“We determined to change our name to reflect the current focus of our company,” said John M. Siebert, Ph.D., Chief Executive Officer of CyDex Pharmaceuticals. “The goal is to create an identity that captures the new CyDex, and to maintain a cohesive and professional image in all of our communications.”
About CyDex Pharmaceuticals
CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company developing products and licensing its CAPTISOL® enabling technology. CyDex is developing its own pipeline of products using its enabling technology solutions, and partnering with leading pharmaceutical, specialty pharmaceutical and biotechnology companies. CyDex is a privately held company located in suburban Kansas City. To learn more about the company, please visit www.cydexpharma.com.
CAPTISOL® and Captisol-enabled® are registered trademarks of CyDex Pharmaceuticals, Inc.
Source: CyDex Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
